UK, Tech ReviewUK

New center to deliver GMP-grade stem cells

21.11.2006

Edinburgh – Scottish scientists are well on the way to deliver clinical grade human stem cells to researchers and companies all over the world. “We will soon be able to deliver embryonic stem cells that meet the regulatory requirements,” Edinburgh-based researcher Paul de Sousa told EuroBiotechNews on the occasion of a EUR3 million kick-off funding for the new Roslin Cells Centre (RCC). “We aim to have our first research grade cell lines available for distribution in spring/summer 2007. In parallel we are developing GMP grade stem cells, which, pending UK Human Tissue Authority accreditation, would be compliant with UK and EU regulations for therapeutic use.” The RCC, which is funded by Scottish Enterprise Edinburgh, will be run by Roslin Cells Ltd, a not-for-profit company.
“What distinguishes us from other groups which aspire to produce clinical grade stem cells is that we co-operate with the National Scottish Blood Transfusion Service, who brings in a lot of experience in regulatory compliance. The other significant feature is that we are prepared to distribute cells to researchers or companies for upfront fees for either exclusive or nonexclusive use. Those fees will enable researchers to commercially expand their research without needing to negotiate commercialization licensing rights in the future,” says de Sousa. This could mean significant progress for the stem cell sector. Currently, all stem cell providers demand license fees on any commercial product derived from their stem cells. This could possibly hamper commercialization or the funding of stem cell discoveries. Whilst it is unclear if the European Regulatory Authorities will accept GMP-grade stem cells cultivated in media which contain animal-derived products, the RCC’s cultivation strategy will be diversified. “We will produce cell lines either with or without animal compounds to meet the regulatory requirements.”

UKUK

24.11.2011

London – The European Medicines Agency has recalled all batches of the cancer drugs Busilvex, Velcade and Vidaza manufactured at Boehringer Ingelheim’s Ben Venue Laboratories facility in Bedford, Ohio, from the European market....

UKUK

14.11.2011

London – GlaxoSmithKline goes west. The British pharmaceutical company launched the $50-million GSK Canada Life Sciences Innovation Fund that will invest in “early-stage breakthrough research” in health care life science in...

UKUK

04.10.2011

Heidelberg/Cambridge/London– A team of researchers from GlaxoSmithKline, the biotech company Cellzome and from Universities Cambridge, Ulm and Amsterdam have found a promising treatment for mixed lineage (MLL-fusion) leukaemia...

UKUK

01.10.2011

Amersham – GE Healthcare intends to remain a major force in cancer therapy. Based in London, the health business of the US technology giant announced it will be reserving €730m of its total R&D budget over the next five years for...

UKUK

01.10.2011

Wolverhampton – One of the challenges for manufacturers of probiotic foods is getting large enough numbers of the bacteria into the intestines; most perish under the strongly acidic conditions in the stomach. Scientists from the...

UKUK

01.10.2011

Washington – British Shire plc gained more than 10% in late August on the London Stock Exchange after the US FDA approved Firazyr (icatibant) for acute attacks of hereditary angioedema. The compound was developed by Berlin-based...

UKUK

26.09.2011

London – The first clinical trial using human embryonic stem cells will be carried out at the Moorfields Eye hospital in London. Doctors will inject retinal cells into the eyes of 12 patients with Stargardt‘s macular dystrophy, a...

UKUK

20.09.2011

Amersham – GE Healthcare intends to stay a major force in cancer. The health business of the US-technological company, which is based in London, announced to reserve €730m of its total R&D budget over the next five years for...

UKUK

29.08.2011

Cambridge - A new biotech spin off from the University of Cambridge launched with €6.8m venture capital. Newco Mission Therapeutics Ltd. plans to develop cancer drugs targeting enzymes in ubiquitin pathways that control cellular...

Displaying results 21 to 30 out of 396

< Previous 21-30 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-uk/browse/2/article/new-center-to-deliver-gmp-grade-stem-cells.html

Stock list

All quotes

TOP

  • NOVACYT (F)4.99 EUR9.67%
  • CELLECTIS (F)14.00 EUR4.56%
  • PHARMING (NL)0.53 EUR3.92%

FLOP

  • PROSENSA (NL)10.48 USD-16.29%
  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%

TOP

  • SANTHERA (CH)72.55 CHF136.7%
  • CELLECTIS (F)14.00 EUR109.0%
  • ADDEX (CH)3.62 CHF62.3%

FLOP

  • THROMBOGENICS (B)8.78 EUR-51.2%
  • MERCK KGAA (D)64.18 EUR-50.1%
  • VERONA PHARMA (UK)1.20 GBP-43.4%

TOP

  • SANTHERA (CH)72.55 CHF3564.1%
  • GW PHARMACEUTICALS (UK)432.00 GBP802.3%
  • PAION (D)2.92 EUR323.2%

FLOP

  • EVOCUTIS (UK)0.21 GBP-93.3%
  • CYTOS (CH)0.25 CHF-92.8%
  • THROMBOGENICS (B)8.78 EUR-72.8%

No liability assumed, Date: 09.07.2014

Job Advert

Executive Director of the IMI Joint Undertaking

The Innovative Medicines Initiative Joint Undertaking (IMI JU) is a public-private partnership between the European Commission and the European Federation of Pharmaceutical Industries Associations (EFPIA).
The Executive Director will lead and manage the Joint Undertaking and take overall responsibility for its operations ensuring the achievement of the Joint Undertaking's objectives. more...

Current issue

All issues

Product of the week

Products

Events

All Events

Partner-Events

Vilnius (LT)

Life Sciences Baltics